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Abstract 
Clostridioides difficile is the leading cause of infectious diarrhea (Vernaya et al., 2017).  
Probiotics have been proposed to provide a protective benefit against Clostridioides difficile 
infection (CDI). The objective of this literature review was to examine the research evidence 
pertaining to the use of probiotics for the prevention of CDI in individuals receiving antibiotic 
therapy. A systematic literature review of studies published between 2015 and 2019 was 
performed. Five databases were searched, which yielded 10 systematic reviews that met strict 
inclusion criteria. Overall, the majority of evidence indicated that probiotics versus no treatment, 
placebo, or usual care have the potential to reduce CDIs in patients on antibiotic therapy by 50% 
or greater. There was no increased risk of adverse events among those taking probiotics. Benefit 
is greater when the background risk of CDIs was over 5%. The optimal probiotic dose, duration, 
species, and formulation is not known, although multispecies or Lactobacillus probiotics may be 
more effective in addition to taking probiotics within one to two days of starting antibiotics. 
These findings are limited to patients that are not immune compromised, pregnant, elderly, 
critically ill, have not had recent surgery, and do not have prosthetic heart valves. Overall, due to 
the magnitude of the effect of probiotics and their favorable safety profile, providers should 
consider including a shared decision-making conversation with their patients taking antibiotics 
regarding their personal risk versus benefit option to take probiotics concurrently. 
 Keywords: clostridium difficile infection, clostridioides difficile infection, CDI, c. 
difficile, CDAD, clostridum difficile associated diarrhea, AAD, antibiotic associated diarrhea, 
probiotics, lactobacillus, saccharomyces, bifidobacterium,  
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Probiotics and the Prevention of Clostridioides difficile: 
A Review of Existing Systematic Reviews 
 Clostridioides difficile is the leading cause of infectious diarrhea (Vernaya et al., 2017). It 
is also the cause of significant morbidity and mortality (Shen et al., 2017; Vernaya et al., 2017). 
Antibiotics can disrupt the intestinal microbiota, leading to increased susceptibility to the 
Clostridioides difficile pathogen (Goldenberg et al., 2017). Lau and Chamberlain (2016) indicate 
that antibiotic therapy is known to be the most substantial risk factor for Clostridioides difficile 
infection (CDI). Probiotics are living microbial supplements that are used to restore colonic 
microflora (Vernaya et al., 2017). Probiotics are hypothesized to reduce the incidence and 
prevalence of CDI (Vernaya et al., 2017). Probiotics have the potential to protect against CDI 
and are a promising prophylactic therapy. The purpose of this research is to present a synthesis 
of the current evidence regarding probiotics for the prevention of CDI in patients receiving 
antibiotic therapy. The background of CDI and probiotics are explored, an overview of the 
current CDI preventative practices are provided, and the review methods are described. The 
literature review of studies published between 2015 and 2019 are discussed, including a review 
of study characteristics, synthesis of research findings, quality indicators, and gaps in the 
literature. In conclusion, implications for future research, clinical practice, and policy are 
recommended.  
Background 
 Clostridioides difficile, formerly known as Clostridium difficile, is a “gram-positive, 
spore-forming, toxin-producing anaerobic bacterium” (Zhu et al., 2018, para. 2). This pathogen 
is responsible for causing half a million CDIs in 2011 in the United States (Lessa et al., 2015). 
Of those reported infections, 29,300 resulted in death within 30 days of diagnosis (Lessa et al., 
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2015). Recent epidemiological estimates indicate that the national burden of CDIs is decreasing 
(Guh et al., 2020). A 36% decrease in healthcare associated CDIs was found between 2011 and 
2017, no change was found in community acquired CDIs (Guh et al., 2020). While the incidence 
of healthcare associated CDIs was reported to be decreasing, it remains a prominent nosocomial 
infection and is responsible for 12.1% of all healthcare associated infections (Centers for Disease 
Control [CDC], 2018b).  
 The most significant risk factor for CDIs is antibiotic therapy (Lau & Chamberlain, 
2016). Antibiotics reduce the ability of the gastrointestinal microflora to protect against CDIs by 
decreasing its ability to prevent colonization of the Clostridioides difficile pathogen (Parkes, 
2009). Being on an antibiotic increases the risk of CDI by seven to 10 times for the duration of 
antibiotic therapy and for 30 days thereafter (CDC, 2018a). Certain antibiotic classes have also 
been found to increase the risk of CDIs; these classes are the fluoroquinolones, third and fourth 
generation cephalosporins, clindamycin, and carbapenems (CDC, 2018b). In addition, the 
concurrent use of two or more antibiotics increases the risk of CDI (Johnston et al., 2018). 
Lastly, certain patient populations are at an increased risk for CDIs. Those at an increased risk 
include those who (a) are over the age of 65, (b) are immune compromised from medications or 
disease states, (c) have stayed in a hospital or long term care facility, (d) have had a previous 
CDI or exposure to CDI, (e) are undergoing gastrointestinal surgeries or procedures, and 
possibly (f) are taking proton pump inhibitors or histamine 2 blockers (CDC, 2018b).  
 Probiotics, defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host” (Hill et al., 2014, p. 506) have come under 
consideration as a potential prophylactic therapy for preventing CDIs in patients receiving 
antibiotic therapy. Probiotics have been proposed to work, as shown in animal and cellular 
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studies, by preventing gastrointestinal colonization, adhesion, and invasion by the CDI pathogen 
in addition to stimulating the immune system (Parkes, 2009). The current approach for 
preventing CDIs includes placing patients with a known or suspected CDI into contact 
precautions, adherence to recommended hand hygiene practices, environmental cleaning with a 
CDI sporicidal agent, and utilizing antibiotic stewardship programs (CDC, 2019). Current 
guidelines do not recommend probiotics as a preventative strategy, despite having the highest 
quality evidence of the previously stated prophylactic strategies (Lytvyn et al., 2016).  
 The clinical significance of preventing CDIs is found in the sequela of CDI patients’ 
experience, the economic burden of CDIs to the healthcare system, and the potential cost 
effectiveness of probiotics. In addition, the United States National Action Plan goal is to reduce 
CDIs by 50% by the year 2020 (CDC, 2015). Patients with CDIs experience distressing 
symptoms such as severe diarrhea, dehydration, and colitis (CDC, 2018a). More rare but serious 
consequences such as sepsis, toxic megacolon, and death are also possible consequences of CDIs 
(CDC, 2018a). In addition to experiencing the physical symptoms of pain and discomfort, 
patients also miss work and spend time hospitalized due to CDIs. The economic burden of CDIs 
is significant, with a reported cost of $5.4 billion dollars in 2014 between both community and 
healthcare associated costs (Desi et al., 2016). Probiotics may provide a cost effective strategy to 
reduce the incidence of CDIs, (Shen, Leff et al., 2017; Shen, Maw et al., 2017). Overall, 
reducing the incidence of CDIs would yield health and economic benefits to patients and 
healthcare systems alike as well as contribute to meeting The United States National Action 
Plan’s CDI reduction goal.  
 The findings of this research have the potential to inform advanced practice registered 
nurse (APRN) practice and may cause APRNs to consider including a shared decision making 
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discussion about the potential benefit of probiotics with their patients that need antibiotic 
therapy. Furthermore, this research should be used to inform the development or reevaluation of 
current clinical guidelines regarding CDI prevention.  
 Based on the phenomena of interest, a clinical question was developed which utilized the 
PICO framework (Melnyk & Fineout-Overholt, 2015): population (P), intervention (I), 
comparison (C), and outcome (O). This literature review sought to answer the following PICO 
question: In individuals receiving antibiotic therapy (P) how does receiving probiotics (I) versus 
not receiving probiotics (C) prevention affect the prevention of Clostridioides difficile (O)?  
Methods 
 A review of the literature was conducted with the following methods. To begin, the 
following databases were selected, CINAHL Plus with Full Text, Cochrane Database of 
Systematic reviews, MEDLINE, MEDLINE (PubMed), and EBSCOMegaFILE. Four of the 
databases were searched between January 2013 and November 2019. EBSCOMegaFILE was 
searched between January 2015 and November 2019, due to refined search criteria to include 
studies from the past five years. General search restrictions were used to identify full text, peer-
reviewed, articles written in the English language. Details on specific search restrictions used for 
each database, along with the general subjects covered by database, have been provided (See 
Table 1 in the Appendix section).  
 The following keywords were used to search all databases: “Clostridium difficile,” 
“Clostridioides difficile,” “C. difficile,” “C. diff,” “CDAD,” “Clostridium difficile associated 
diarrhea,” “AAD,” “antibiotic associated diarrhea,” “C. difficile associated diarrhea,” “C. diff 
associated diarrhea,” “probiotic,” “prevention,” “prophylaxis.” “CDI,” “Saccharomyces, 
“Lactobaccillus” “Bifidobacterium,” and “systematic review.” Details on specific keyword 
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combinations that were used and the number of hits for each search have been provided (See 
Table 2 in the Appendix section).  
	 All cells in Table 2 that had 10 or less search hits were then reviewed. This review 
yielded 148 abstracts that were screened for inclusion or exclusion, 66 of these were duplicates. 
Inclusion criteria for Table 3 included (a) systematic reviews with or without meta-analysis of 
randomized controlled trials; (b) intervention needed to compare a probiotic to a placebo, no 
treatment, or usual care in patients being administered antibiotic therapy; (c) incidence of CDI 
needed to be reported as either a primary or secondary outcome; and (d) included adult and/or 
pediatric sample populations from inpatient or outpatient settings. Additionally, the systematic 
review could include any strain, formulation, duration, or dose of the probiotic intervention. Any 
systematic reviews that did not meet the criteria were then excluded. While the initial search 
period was between January 2013 and November 2019, articles were narrowed further to include 
only systematic reviews that were published in the year 2015 or after, in an effort to include the 
most recent evidence.   
 Ten systematic reviews were identified for inclusion in Table 4. Each systematic review 
was reviewed in its entirety. Nine of these systematic reviews included a meta-analysis. Seven of 
these studies reported CDI as a primary outcome and three of these studies reported CDI as a 
secondary outcome to antibiotic-associated diarrhea. Table 4 includes columns that describe each 
systematic review’s design, number of randomized controlled trials, number of subjects, sample 
characteristics, description of probiotic intervention, and major findings.  
Summary of the Literature: Characteristics of Included Reviews  
 
 Of the 10 systematic reviews included, the mean number of randomized controlled trials 
included in each review was 17.2, and ranged between 5 and 31. The number of subjects 
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included in each review ranged between 2,020 and 7,967. Seven of these studies reported CDI as 
a primary outcome, whereas three of these studies reported CDI as a secondary outcome to 
antibiotic-associated diarrhea. Five reviews included randomized controlled trials that included 
inpatients and outpatients, three reviews included inpatients only, one review included only 
outpatients, and one review did not specify inpatients or outpatients. Five reviews included adult 
and pediatric subjects, two reviews specified adult subjects (≥	18 years old) only, two studies 
specified older adults only (adults ≥60 years old; adults ≥	65 years old), one review did not 
specify whether adult or pediatric participants were included but reported a mean participant age 
of 43.2 years, no reviews included only pediatric subjects.  
 The characteristics of the probiotic interventions included amongst the reviews varied. 
Six reviews generally included randomized controlled trials that used any probiotic strain, any 
dose, any duration, and any formulation for the probiotic intervention (Cai et al., 2018; 
Goldenberg et al., 2017; Johnston et al., 2018; Lau & Chamberlain, 2016; Shen et al., 2017; 
Vernaya et al., 2017). In contrast, other reviews had specified criteria for characteristics of the 
probiotic intervention such as probiotic species, duration, and/or timing. One review by Xie et al. 
(2015) included six probiotic species, and no dose, duration, or formulation criteria were stated. 
The following genera of species were included in Xie et al. (2015): Lactobacillus, 
Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus alone or in 
combination. Another review included only Lactobacillus alone or in combination, in any dose 
or duration (Sinclair et al., 2016). In the review by Szajewska and Kołodziej (2015) only 
Saccharomyces boulardii, in any dose or duration was included. Lastly, one review did not state 
inclusion criteria for probiotic species in their methods though reported that five different types 
of probiotics were described amongst their included randomized controlled trials (McFarland, 
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2015). The five types of probiotics included in McFarland (2015) were: Saccharomyces 
boulardii, Lactobacillus rhamnosus GG, Lactobacillus Casei DN114001, L. acidophilus + 
Bifidobacterium bifidum, and Lactobacillus acidophilus + Lactobacillus casei + Lactobacillus 
rhamnosus. One review specifically included only randomized controlled trials that indicated the 
probiotic intervention was administered within 3 days of the start of antibiotic therapy and 
continued for the duration of antibiotic course (Lau & Chamberlain, 2016).  
 Generally, all of the systematic reviews included subjects receiving any type of antibiotic 
regimen, who were receiving it for any indication. Therefore, the types of antibiotic therapy and 
indications for antibiotic therapy being administered to the intervention and control group 
subjects varied amongst all systematic reviews. Only one systematic review specified that only 
oral antibiotics were included (Cai et al., 2018).  
Synthesis of Major Systemic Review Findings 
Incidence of CDI  
 The incidence of CDIs reported in the subjects that received the probiotic intervention 
while on antibiotic therapy varied by systematic review, some reported statistically significant 
reductions in CDIs whereas others reported no preventative effect was found. These findings also 
varied amongst probiotic strains and patient populations. To begin, eight of the 10 systematic 
reviews reported findings to suggest efficacy of probiotics in the preventions of CDIs. A 58%-
75% statistically significant reduction in the incidence of CDI in the pooled probiotic 
intervention groups was reported amongst five of the reviews (Goldenberg et al., 2017; Johnston 
et al., 2018; Lau & Chamberlain, 2016; Shen et al., 2017; Sinclair et al., 2016). Another reported 
a statistically significant odds reduction of CDI of 75% and 96% with regard to specific probiotic 
strains (Cai et al., 2017). McFarland (2015) found that four probiotic types were effective in the 
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prevention of CDI and these findings were also statistically significant. Two reviews reported no 
preventative effect of probiotic use (Vernaya et al., 2017; Xie et al., 2015). Finally, Szajewska 
and Kołodziej (2015) found probiotics to be statically significant in the reduction of CDI risk by 
75% in the pediatric patient population.  
Adverse Events 
 
 Adverse events were reported to be similar between probiotic and control groups amongst 
the four studies that reported on adverse events (Goldenberg et al., 2017; Johnston et al., 2018; 
Shen et al., 2017; Szajewska, & Kołodziej, 2015). None of these reviews found that there was a 
noteworthy increased risk of adverse events in the intervention groups taking probiotics. Two 
studies actually reported a somewhat reduced incidence of adverse events in the probiotic group 
(Goldenberg et al., 2017; Shen et al., 2017). Goldenberg et al. (2017) reported a statistically 
significant (P=0.02) incidence of adverse events of 14.3% in the probiotic group versus a 17% 
incidence in the control group (p. 15). Shen et al. (2017) found an adverse event incidence of 
14.2% for the probiotic group in comparison to an incidence of 15.9% in the control group (p. 
1894). Johnston et al. (2018) reported an incidence of 12.4% in the probiotic group compared to 
a 12.1% incidence in the control group (p. 775). Lastly, Szajewska and Kołodziej (2015) simply 
stated that there were similar rates of incidence between the control and probiotic groups but did 
not explicitly report the rates of adverse event incidence nor its statistical significance.   
 Commonly reported adverse events in the largest systematic review included abdominal 
cramping, fever, flatulence, nausea, and taste disturbance (Goldenberg et al., 2017, p. 15). 
Serious adverse events were identified as bacteremia, fungemia, and sepsis. These events were 
not reported in some reviews and others reported them but did not attribute them to the probiotic 
intervention (Goldenberg et al., 2017; Johnston et al., 2018; Shen et al., 2017).  
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Probiotic Species and Strain Specific Efficacy  
 Several studies identified probiotic species and/or strains with superior efficacy in 
prevention CDI. To begin, Johnston et al. (2017) found a statistically significant treatment effect, 
where multispecies probiotics significantly reduced CDIs when compared to no probiotics 
(P<.0001), this is in contrast to the statistically insignificant effect of single species probiotics 
(P=.051). A multispecies mix of probiotics was also found to be statistically significant by Lau 
and Chamberlain (2016) in addition to five single Lactobacillus strains (L. GG, L. acidophilus, L. 
casei, L. rhamnosus, L.plantarum) and the Saccharomyces boulardii strain. Sinclair et al. (2016) 
included only Lactobacillus species in their review and found a large statistically significant risk 
reduction associated with Lactobacillus prophylaxis, regardless if it was given alone or in 
combination with other strains. Shen et al. (2017) also found a favorable effect for Lactobacillus 
only and Lactobacillus in combinations with Streptococcus or Streptococcus + Bifidobacterium 
species subgroups, which were statistically significant. Of eight probiotic regimes Cai et al. 
(2018) found two Lactobacillus strains that had superior efficacy and were statistically 
significant in reducing the risk of CDIs, these are the L. casei and L. acidophilus strains. 
McFarland (2015) found two probiotic single strains to have a statistically significant effect; 
these are Saccharomyces boulardii, and Lactobacillus Casei DN114001. In addition, McFarland 
(2015) found two combinations of species and/or strains to have a statistically significant effect, 
Lactobacillus acidophilus + Bifidobacterium bifidum and Lactobacillus acidophilus + 
Lactobacillus casei + Lactobacillus rhamnosus (McFarland, 2015). Saccharomyces boulardii, 
was the only probiotic strain included in the review by Szajewska and Kołodziej (2015) which 
demonstrated a lower rate of CDI in the Saccharomyces boulardii intervention group, but it was 
not statistically significant in the pooled analysis. Likewise, Johnston et al. (2018) performed a 
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post hoc subgroup analysis of Saccharomyces boulardii in their study and found no significant 
difference in efficacy against CDIs when compared against trials using other species. Shen et al. 
(2017) found no statistically significant efficacy for a specific probiotic formulation, nor did 
Goldenberg et al. (2017).  
Efficacy in Select Patient Populations 
 Several systematic reviews performed subgroup analyses on select patient populations 
including adults, pediatrics, inpatients, and outpatients. To begin, the findings in regard to the 
adult and pediatric populations are as follows. Three reviews, all which reported statistically 
significant reduction of CDIs in their pooled intervention groups, found no difference in 
probiotic efficacy across adult or pediatric age groups (Goldenberg et al., 2017; Johnston et al., 
2018; McFarland, 2015). Similarly, Lau and Chamberlain (2016) found statistically significant 
efficacy for both adults and pediatric patients with a slightly higher risk reduction in pediatric 
patients, of 59.5% (P<0.001) and 65.9% (P=0.008) respectively. Only one review by Szajewska 
and Kołodziej, (2015) found that probiotics reduced the risk of CDIs in the pediatric population 
by 75% (P=0.01) but not in adults (P=0.39). Two reviews, that included only older adults, ≥60 
years of age, found no efficacy of probiotics and prevention of CDI in the older patient 
population (Vernaya et al., 2017; Xie et al., 2015). 
 Next, there were several findings regarding inpatient and outpatient populations. The 
efficacy of probiotics in hospitalized adult patients was statistically significant at a 58% 
(P<0.001) risk reduction as reported by Shen et al (2017) and a 75% risk reductions by Sinclair 
et al (2016). A greater benefit was found in hospitalized patients, where a statistically significant 
risk reduction of 61% (P=<0.001) was found versus a statistically insignificant 69.4% (P=0.468) 
risk reduction in outpatients (Lau & Chamberlain, 2016, p. 31). One review included only 
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outpatients, which found two specific probiotic strains to be effective in reducing the odds of 
CDI in this population (Cai et al., 2018).  
Timing of Probiotic Administration 
 Timing of administration of the probiotic intervention in relation to when antibiotic 
therapy is started was a major finding across two studies. Shen et al. (2017) was the only review 
to perform a sensitivity analysis to evaluate the effect of probiotic timing on the prevention of 
CDI, and all probiotics were found to be more effective when administered closest to the first 
dose of antibiotics. A statistically significant reduction in efficacy was found for every day 
probiotics were delayed (Shen et al., 2017). The highest efficacy was found when probiotics 
were started within two days of antibiotic therapy (Shen et al., 2017, p. 1894). Probiotics 
administered three to seven days after starting antibiotics had only a 30% CDI risk reduction 
whereas when administered within 1 to 2 days after starting antibiotics the efficacy increased to 
68% (P=0.02) and was statistically significant (Shen et al., 2017, p. 1894). Moreover, the 
significant reduction (60.5%) in CDIs in the pooled probiotic intervention group reported by Lau 
and Chamberlain (2016) may in part be due to the inclusion of only randomized controlled trials 
where the probiotic intervention was initiated within three days of antibiotic therapy. This was 
the only review to do so among the included studies.   
Baseline Risk 
 Another finding validated by several reviews was that the efficacy of probiotics for the 
prevention of CDIs when there is a certain level of baseline risk. A greater prophylactic benefit 
was found when the baseline risk of CDI was >5%, which increased the risk reduction to 70% 
(P=0.01) from 60% (Goldenberg et al., 2017, p. 17). Likewise, Sinclair et al. (2016) reported that 
a baseline risk of CDI of ≥ 6%, increased the risk reduction to 83% from 75% (p. e714-e715). 
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Finally, another review also found that a CDI incidence rate of ≥5% is likely to improve the 
efficacy of probiotics (Johnston et al., 2018, p. 777). 
Quality Indicators  
 The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
criterion was used by six of the systematic review authors to transparently evaluate the quality of 
evidence regarding their findings on the efficacy of probiotics for preventing CDIs (Guyatt et al., 
2008). While all 10 systematic reviews included in this review are considered to be grade I level 
evidence, the GRADE criterion helps further determine how much confidence readers can put 
into the findings of each systematic review (Guyett et al., 2008). The amount of confidence that 
can be put into the evidence can be impacted by: study limitations, inconsistency of results, 
indirectness of results, imprecision, and reporting bias (Guyett et al., 2008). There are four 
GRADE levels of quality: “very-low,” “low,” “moderate,” and “high” (Guyett et al., 2008). 
Overall, the quality of the evidence varied amongst the six systematic reviews that utilized the 
GRADE approach. It was reported to be “very-low” by one study (Sinclair et al., 2016), 
“moderate” by four studies (Cai et al., 2017; Goldenberg et al., 2017; Johnston et al., 2018; 
Szajewska & Kolodziej, 2015), and “high” by one study (Shen et al., 2017). The remaining four 
systematic reviews did not report the quality of their evidence with the GRADE criterion. 
 Quality considerations for the remaining four systematic reviews that did not report a 
GRADE rating include heterogeneity, methodological quality, missing data, and bias. To start, 
heterogeneity amongst the included randomized controlled trials was a limitation noted by three 
of the remaining systematic reviews (Lau & Chamberlain, 2016; Vernaya et al., 2017). Lau and 
Chamberlain (2016) reported no significant heterogeneity between the randomized controlled 
studies that were included (I²=0.000). Although Lau and Chamberlain (2016) acknowledged that 
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there was variation between enrollment criteria of subjects, probiotic intervention characteristics, 
antibiotic regimens, CDI testing and diagnosing, and the follow up period (Lau & Chamberlain, 
2016). McFarland (2015) reported a low level of heterogeneity (I²=17.2%). In contrast, Vernaya 
et al. (2017) found a moderate level of heterogeneity amongst their included randomized 
controlled trials (I²=46%).  
 Two systematic reviews included a measure of methodological quality. Xie et al. (2015) 
reported that the overall quality of the randomized controlled trials in their systematic review 
were of moderate methodological quality, heterogeneity in their review was not explicitly stated 
nor measured. Furthermore, Vernaya et al. (2017) reported moderate to high methodological 
quality for the five randomized controlled trials in their review. Missing data was also discussed 
as a limitation by all three of the systematic reviews (Lau & Chamberlain, 2016; McFarland, 
2015; Vernaya et al., 2017).  
 In addition, publication bias was assessed for in two of the reviews. A funnel plot was 
utilized by both Lau and Chamberlain (2016) and McFarland (2015), which found no evidence 
of publication bias in either review. Lastly, a concern for potential researcher bias was identified 
in the systematic review by McFarland (2016). McFarland (2016) disclosed a conflict of interest 
because of participation on the scientific advisory board for BioK+, one of the probiotic 
formulations included in the author’s systematic review. The study included four randomized 
controlled trials that utilized the BioK+ formulation as an intervention (McFarland, 2016). This 
affiliation could affect the quality of this researcher’s reporting of the data and findings.  
 Overall, there was vast variability in the designs, quality, and heterogeneity of the 
randomized controlled trials included amongst the 10 systematic reviews. Variability was 
identified amongst the types of probiotic species and strains, variability in antibiotics that 
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subjects were taking during the studies, and variability in the doses, duration, and formulations 
of probiotic interventions. These differences impact how much trust can be placed in the major 
findings. The major findings from this literature review of existing systematic reviews can be 
interpreted with these quality indicators in mind. 
Discussion 
 The findings from this review of 10 existing systematic reviews leaves us with several 
important points regarding the efficacy, safety, optimal probiotic species, and timing of 
administration of probiotics as a prophylactic therapy for CDIs in patients receiving antibiotic 
therapy. Overall, the majority of the evidence reviewed suggests that probiotics have the 
potential to be an effective prophylactic therapy for preventing CDIs. As relative to no 
probiotics, placebo or usual care, six of the 10 meta-analyses reported CDI risk reduction rates of 
58%-75% when probiotics were administered to patients receiving antibiotics (Goldenberg et al., 
2017; Johnston et al., 2018; Lau & Chamberlain, 2016; Shen et al., 2017; Sinclair et al., 2016). 
Two additional reviews found efficacy for certain probiotic strains in reducing CDIs (Cai et al., 
2018; McFarland, 2015). Two of the reviews on older adults found no preventative effect 
(Vernaya et al., 2017; Xie et al., 2015). One review found efficacy in the pediatric population but 
not adult (Szajewska & Kołodziej, 2015).	It must be noted that the quality of the evidence varied 
amongst these reviews, ranging from “very-low” to “high.” This variability in GRADE quality 
does affect the overall level of confidence we can put into the synthesized findings.  
 The finding regarding a superior probiotic species or strain was uncertain. Multispecies 
mixes were found to be beneficial (Johnston et al., 2017; Lau & Chamberlain, 2016; McFarland, 
2016). Two single species of probiotics that demonstrated greater efficacy are the Lactobacillus 
and Sacchromyces boulardii species. Of the Lactobacillus strains, Lactobacillus casei was found 
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to be superior in two reviews (Cai et al., 2018; McFarland, 2016). Evidence on the Sacchromyces 
boulardii strain is mixed, two reviews indicated superior efficacy, whereas one other found no 
statistically significant efficacy (Lau & Chamberlain, 2016; McFarland, 2016; Szajewska & 
Kołodziej, 2015). Two reviews that reported large magnitudes of effect of probiotics reducing 
the incidence of CDIs did not identify a single probiotic species or formulation that was superior 
to another (Goldenberg et al., 2017; Shen et al., 2017). While a certain probiotic species, strains, 
or combinations thereof, may yield the greatest benefit, though this remains unknown. 
Furthermore, most probiotics are regulated as a dietary supplement, and thus do not require 
approval by the Food and Drug Administration (FDA) before being sold to consumers (National 
Center for Complimentary and Integrative Health [NCCIH], 2019). Consideration must also be 
given to the potential for variability in quality and purity amongst these over the counter 
products. Probiotics being sold to specifically treat a disease will have undergone testing for 
efficacy and safety and will have been approved by the FDA (NCCIH, 2019).  
 Probiotics appear to have a favorable safety and side effect profile as all of the reviews 
that reported on adverse events found a similar rate of adverse events between the probiotic 
intervention group and the control groups, some even reported a lower rate of adverse events in 
the probiotic groups. Common adverse events reported included: abdominal cramping, fever, 
flatulence, nausea, and taste disturbance (Goldenberg et al., 2017). Severe adverse events, 
bacteremia, fungemia, and sepsis, were reported but not attributed to probiotics.  
 Patients in both the adult and pediatric populations appeared to gain a protective benefit 
against CDIs from the administration of probiotics when on antibiotic therapy. The only 
population found not to confer a protective benefit from probiotics were patients’ age 60 and 
older. Other populations that were found to benefit were inpatients and outpatients, but more 
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benefit was seen in hospitalized patients (Lau & Chamberlain, 2016; Shen et al., 2017; Sinclair et 
al., 2016). While benefit was found in these populations, it must be known that certain patient 
populations were excluded from many of the randomized controlled trials included in these 
reviews. Generally, those that were excluded include immune compromised, pregnant, elderly, 
critically ill, surgical patients, and patients with prosthetic heart valves. Therefore, the efficacy 
and safety of probiotics is not known for these unique populations. 
 This review also found that both the timing of administration and that the inherent 
background risks are important variables in increasing the efficacy of probiotics for the 
prevention of CDI. Several of the reviews reported increased efficacy of probiotics for the 
prevention of CDIs in populations that had a higher baseline risk of CDIs, reported as greater 
than 5-6% (Goldenberg et al., 2017; Johnston et al., 2018; Sinclair et al., 2016). The greater 
benefit seen in hospitalized patients in this review could perhaps be due to the inherently higher 
baseline CDI risk in this population. Hospitals and other inpatient care facilities should identify 
their unique baseline risk of CDIs to determine if their patient populations would confer an even 
greater protective benefit from probiotics. If a provider or facility decides to implement 
prophylactic probiotics, evidence suggests that it is best to begin probiotics at the time of 
beginning antibiotics or within one to two days for the greatest benefit (Shen et al., 2017). 
 Lastly, probiotics may be a cost-effective prophylactic intervention. One study found 
probiotics to be a cost-effective prophylactic therapy in hospitalized patients 65 years of age or 
older (Shen, Leff, Schneider et al., 2017). Likewise, Shen et al. (2017) reported that probiotics 
have the potential to save approximately 500 million dollars a year.  
Future Implications  
Clinical Practice Recommendations  
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 APRN’s are in a key role to help reduce the incidence of CDIs. This can be accomplished 
by first always adhering to the best practices for antibiotic stewardship in their practice. Second, 
when antibiotics are clinically indicated APRN’s should engage in a shared decision-making 
conversation with their patients regarding their option to take probiotics, in those whom 
probiotics are deemed appropriate for. Those appropriate for probiotics would be patients that are 
not immune compromised, pregnant, elderly, critically ill, surgical patients, or patients with 
prosthetic heart valves The APRN could recommend a multispecies probiotic or one containing 
Lactobacillus. Furthermore, the APRN would emphasize the importance of starting the probiotic 
as close to the start of the antibiotic and for the duration of the course of antibiotics. Overall, this 
conversation should include a brief discussion on the current evidence on the efficacy and safety 
of probiotics in the prevention of CDIs, with the goal of fully informing our patients on their 
option to take probiotics concurrently with their antibiotic prescription.  
Recommendations for Research  
 Several gaps in the literature have been identified through this review of the literature. 
First, while there is strong evidence of little to no adverse events in patients receiving probiotics, 
this finding is limited to certain patients as most randomized controlled trials examined in these 
10 systematic reviews excluded similar patients. The types of patients generally excluded were, 
immune compromised, pregnant patients, elderly, critically ill patients, surgical patients, and 
patients with prosthetic heart valves. This yields a large gap in the literature regarding the safety 
and efficacy of the use of probiotics in these patients. Since several of these patient populations 
are at higher risk for CDI, consideration should be given to performing randomized controlled 
trials specifically in these populations to determine if they can be used safely and effectively.  
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 Next, two systematic reviews with the smallest number of randomized controlled trials 
were those that included only patients 60 years of age and older. Since this is a patient population 
that is at increased risk for CDIs, more randomized controlled trials are necessary to determine if 
this population could confer benefit from probiotics.   
 Lastly, while the efficacy of probiotics in the prevention of CDIs was demonstrated in 
several systematic reviews, most of the systematic reviews included randomized controlled trials 
that included any probiotic species, dose, duration, or formulation, as well as any type of 
antibiotic. This leaves us with a large remaining question; just what is the optimal probiotic 
species (or mix of species), dose, duration of therapy, and formulation (pill, yogurt, liquid, 
powder)? Or furthermore, could a certain probiotic work best to prevent CDIs in patients that are 
on a specific antibiotic or antibiotic class. Large scale randomized controlled studies comparing 
single species probiotics, multispecies probiotics, doses, durations, and formulations while 
controlling for certain antibiotics could yield findings to identify optimal probiotic prophylaxis. 
Education Recommendations 
 As discussed previously APRNs are in a key role to help reduce the incidence of CDIs. 
To accomplish this, APRNs must first receive formal education regarding the state of the current 
evidence on probiotics for the prevention of CDIs in patients receiving antibiotic therapy on 
which to guide their practice. Formal education on the findings of this literature review can be 
disseminated to the APRN population by the following means: published article, employer 
facilitated training, PowerPoint presentation, APRN curricula, and/or updated clinical practice 
guidelines.   
Recommendations for Policy  
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 The majority of the research reviewed suggests that probiotics are effective in preventing 
CDIs in patients on antibiotic therapy, in addition to having little to no adverse effects in a 
patient population that is not immunocompromised, pregnant, elderly, critically ill, surgical 
patients, and without prosthetic heart valves. While the optimal probiotic is not known, the 
evidence indicates that any probiotic versus no probiotic is generally more effective against 
CDIs. Current guidelines do not reflect this evidence, and consideration should be given to 
updating relevant guidelines to include a recommendation to providers on the individualized use 
of probiotics for CDI prophylaxis.  
Conclusion 
 CDIs present a substantial burden to our healthcare systems, patients, and economy. The 
findings from this review of existing systematic reviews has the potential to reduce these burdens 
and help us meet the United States National Action Plans goal to reduce CDIs by 50% in 2020. 
The findings suggest that any probiotic versus no probiotic in patients receiving antibiotic 
therapy may help reduce their risk of CDIs. The optimal probiotic species, strain, dose, duration, 
and formulation is not known, but a multispecies probiotic or those containing Lactobacillus 
could be recommended. If probiotics are administered, they should be given ideally within one to 
two days of the start of antibiotics. Furthermore, patients that are immune compromised, 
pregnant, elderly, had recent surgery, or have a prosthetic heart valve should not receive 
probiotics due to the unknown efficacy and safety in these populations. Because current 
guidelines do not include a recommendation on prophylactic probiotic therapy, the decision to 
incorporate a probiotic into the patient’s plan of care should be a shared decision between the 
provider and patient. This decision can be made once the patient has been fully informed about 
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the current state of the evidence and their individualized risk versus benefit of taking a probiotic 
concurrently with their prescribed antibiotic.  
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